Population Pharmacokinetics and Pharmacodynamics of Albinterferon Alfa-2b in Patients Treated for Hepatitis C Virus Genotype 2/3

By Yu Jing   Sun Haiying   Pang Maria   Chuang Wan-Long   Sarin Shiv K.   Flisiak Robert   Stein Daniel S.  

Anti-Infective Agents, Vol. 12, Iss. 1, 2014-01 ,pp. : 58-67

Bentham Science Publishers

Access to resources Recommend Favorite

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C

By Xu C.   Gupta S.   Krishna G.   Cutler D.   Wirth S.   Galoppo C.   Ciocca M.   Kolz K.   Noviello S.   Sniukiene V.  

European Journal of Clinical Pharmacology, Vol. 69, Iss. 12, 2013-12 ,pp. : 2045-2054

Springer Publishing Company

Access to resources Recommend Favorite

Generalised Dermatitis Induced by Pegylated Interferon- -2b in a Patient Infected with Genotype-1 Hepatitis C Virus: Presentation of a Case

By Gallelli L.  

Clinical Drug Investigation, Vol. 25, Iss. 4, 2005-01 ,pp. : 281-284

Adis International

Access to resources Recommend Favorite

The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells

By  

Current Pharmaceutical Design, Vol. 10, Iss. 17, 2004-01 ,pp. : 2093-2100

Bentham Science Publishers

Access to resources Recommend Favorite

Short-Term Therapy for Patients with Hepatitis C Virus Genotype 2 or 3 Infection

By Dalgard Olav  

Drugs, Vol. 66, Iss. 14, 2006-01 ,pp. : 1807-1815

Adis International

Access to resources Recommend Favorite